Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

Zevra Therapeutics (ZVRA) Long-Term Debt Repayments: 2014-2024

Historic Long-Term Debt Repayments for Zevra Therapeutics (ZVRA) over the last 4 years, with Jun 2024 value amounting to $42.7 million.

  • Zevra Therapeutics' Long-Term Debt Repayments rose 20528.02% to $42.7 million in Q2 2024 from the same period last year, while for Jun 2024 it was $47.4 million, marking a year-over-year decrease of 6.97%. This contributed to the annual value of $42.7 million for FY2024, which is 143.57% up from last year.
  • According to the latest figures from Q2 2024, Zevra Therapeutics' Long-Term Debt Repayments is $42.7 million, which was up 802.56% from $4.7 million recorded in Q4 2023.
  • Zevra Therapeutics' 5-year Long-Term Debt Repayments high stood at $42.7 million for Q2 2024, and its period low was -$207,000 during Q3 2023.
  • For the 2-year period, Zevra Therapeutics' Long-Term Debt Repayments averaged around $12.0 million, with its median value being $4.7 million (2023).
  • Data for Zevra Therapeutics' Long-Term Debt Repayments shows a peak YoY spiked of 20,528.02% (in 2024) over the last 5 years.
  • Over the past 3 years, Zevra Therapeutics' Long-Term Debt Repayments (Quarterly) stood at $37.9 million in 2021, then reached $4.7 million in 2023, then skyrocketed by 20,528.02% to $42.7 million in 2024.
  • Its last three reported values are $42.7 million in Q2 2024, $4.7 million for Q4 2023, and -$207,000 during Q3 2023.